Talking About Glaucoma (AAC)
Claim This Podcastby Robert M Schertzer, MD, MEd, FRCSC
Podcast Overview
<p>Prior to episode 30, this AAC version had chapter markings. From episode 30 onward, both the AAC and mp3 versions are identical.</p>
Language
🇺🇲
Publishing Since
3/12/2009
1 verified contact email on file for Talking About Glaucoma (AAC)
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 20, 2024
Managing dry eye in Glaucoma with Mahnia Madan, ep 40 (AAC)
In this episode, Dr. Mahnia Madan and I discuss the challenges of managing glaucoma and dry eye conditions. We explore the impact of glaucoma medications on dry eyes, the importance of tailored treatment plans, cyclosporines, lid hygiene, in-office therapies like IPL, and the collaborative approach between optometrists and ophthalmologists. The discussion emphasizes the need for personalized care to improve patients' quality of life.
April 9, 2024
VR Visual Field testing with Abdullah Sarhan, ep 39
In this episode, I talk with Abdullah “Abed” Sarhan, CEO and Co-founder of Retinal Logic, about the company's use of AR and VR technology for vision screening. Abbott shares his background in deep learning and healthcare, the development of the virtual reality prototype, the device's availability and Health Canada approval, and its differentiation from other companies' technologies. He also discusses the various test sizes and algorithms available, ongoing research, user experience, and the company's future roadmap.
October 24, 2023
OCT Beyond the Basics with Hady Saheb, ep 38 (AAC)
Going beyond the basics with Optic Coherence Tomography with Hady Saheb. Our discussion includes Ganglion Cell Layer analysis, structure-function correlation, the floor effect, viewing-software vs printouts and explaining test results to patients.
40 total episodes available
Deep-dive analytics for Talking About Glaucoma (AAC)
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Talking About Glaucoma (AAC)?
<p>Prior to episode 30, this AAC version had chapter markings. From episode 30 onward, both the AAC and mp3 versions are identical.</p> - How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.